Author: BioProNET Network – Page 2

Outcomes of IBSCA funding

BioProNET recently funded 7 Industrial Biotechnology Seeding Catalyst Award. These awards were designed to accelerate translational research by developing and progressing research along the technology readiness level (TRL) pathway, increasing business—academic engagement and company leverage on innovation activities, as well as generating data to support applications for larger grant funding. Below are the key aims and outcomes from each of these projects.

Download a pdf here

STARS School 2018: Embedding the Industrial Perspective

BBSRC Strategic Training Awards for Research Skills (STARS) School 2018: Embedding the Industrial Perspective

For Early Career Researchers: The Bioprocessing Skills School

Do you want to find out how your career might develop working for industry, the differences between industrial- and academic-driven research and how the industrial environment matches your career ambitions?  Here’s your opportunity to answer these questions and find out much more about your ability to work in teams and how the innovative, entrepreneurial spirit drives research translation.

At our week-long, intensive residential training programme, designed around the insights and advice of senior industrialists, you will take part in group-based activities and work with real-life industrial case studies. The programme is designed to engage with the process of entrepreneurship, focus on the development of the ability to promote research ideas and their value to audiences and the key importance of the societal impact of industrial biotechnology.

Are you interested? If you are (a) an Early Career Researcher (normally undergoing PhD training or on first Post-doctoral positioning in an academic environment but potentially in the early stages of an industrial career), (b) working in the area of bioprocessing of biopharmaceuticals or novel biological therapeutics (c) on a project that has an industrial collaborator then this could be an ideal opportunity for you.

The week-long residential programme is funded by the BBSRC (accommodation, meals and all training activities) to eligible applicants but will be limited to no more than 18 participants each year.  Each participant will be asked to make a £150 non-returnable contribution for registration once their acceptance of a place is confirmed. Informal enquiries can be made to Dr Jo Flannelly (joanne.flannelly@manchester.ac.uk).

The programme will be held on 9th-14th September 2018, inclusive, at the National Biologics Manufacturing Centre (NBMC, Centre for Process Innovation, CPI, Darlington) and the week will start with a delegate networking dinner on the evening of Sunday 9th at the hotel.

The BioProcessing Skills School has been developed by the Universities of Manchester and Kent, in collaboration with the NBMC and BioProNET, and is funded by the BBSRC Strategic Training Awards for Research Skills (STARS).

Details of the full programme will follow and the sessions will include: molecular design and development of biological therapeutics, generating the tools for self awareness, industrial-scale manufacturing process, drug formulation and delivery embedded within a series of industrial site visits and presentations from industrial practitioners and entrepreneurs.

Register here: https://www.surveymonkey.co.uk/r/STARS_2018_Registration

5th Annual Science Meeting

October 10-11th 2018
British Medical Association House, Central London

Thank you to everyone who made this meeting a huge success. Photos will be shared with members once the photos are ready.

Wednesday October 10th
9.30 Registration
10.15-10.30 Welcome, achievements and what next for BioProNET
Designing more efficient cell-expression systems chaired by Mark Smales
10.30-10.55 Kerstin Otte
 University of Applied Science Biberach, Germany Identification and characterisation of intracellular production bottlenecks in CHO cells producing complex biopharmaceuticals
10.55-11.20 Colin Robinson University of Kent Development of next generation E. coli platforms for the regulated production and periplasmic targeting of biotherapeutics
11.20-11.45 Tarit Mukhopadhyay University College London Manufacturing the future at less than a $1 a dose and meeting global health needs
11.45-11.55 Andrew Peden University of Sheffield Developing a toolkit for determining the manufacturability of new therapeutics in CHO cells 
11.55-12.20 Nathan Lewis University of California San Diego, USA Engineering CHO cells with enhanced traits with multiplex genome editing

Building expression systems into optimised process chaired by Yvonne Genzel
13.25-13.50 Gary Finka GlaxoSmithKline Developing a next-generation cell line development platform through targeted automation, analytics and informatics
13.50-14.15 Sophia Hober Royal Institute of Technology, Sweden The human secretome project
14.15-14.25 Mayur Parekh Teesside University Improved preservation of biologics by continuous intensified lyophilisation
14.25-14.35 James Winterburn University of Manchester From bench to business with UKRI funding
14.35–15.00 Natalio Krasnogor Newcastle University Synthetic portabolomics: bridging the gap between the lab bench and industry to speed up the development of new biotech products

The clinic and beyond chaired by Laura Palomares
15.40-16.05 Caroline Barelle Elasmogen soloMERä Biologics: Site-specific therapeutic biologics for the treatment of inflammatory disease
16.05-16.20 Simon Saxby Leaf Expression Systems Plant produced biologics – process economics
16.20-16.30 Michael Plevin University of York Can an archaeal helicase enhance the performance of a nanopore DNA sequencer?
16.30-16.40 Pavlos Kotidis Imperial College London A mathematical model to describe CHO cell growth and monoclonal antibody glycosylation

18.00 Poster session
20.00 Conference dinner

Thursday October 11th
Upstream meets downstream – rapid process development chaired by Cleo Kontoravdi
9.00-9.25 Paul Dalby University College London Analysis and control of protein dynamics and stability: downstream to formulation
9.25-9.50 Yvonne Genzel Max Planck Institute for Dynamics of Complex Technical Systems, Germany Intensified cell-based viral vaccine processes: from continuous to perfusion and to hybrid systems
9.50-10.15 Maiken Kristiansen MedImmune Nucleic acid production for biotherapeutics
10.15-10.25 Dave Brockwell University of Leeds Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
10.25-10.35 Davide Vito University of Kent Translation engineering through the non-coding genome in CHO cells
10.35-11.00 Pernille Harris Technical University of Denmark Solution structure and self-association of pharmaceutical proteins

Molecular characterisation of process quality chaired by Alan Dickson
11.40-12.05 Mike Betenbaugh Johns Hopkins University, USA Glycoengineering of mammalian cell lines to improve product quality
12.05-12.30 Laura Palomares National Autonomous University of Mexico Challenges of bringing recombinant vaccines to the market: A case study for a influenza vaccine
12.30-12.40 Perdita Barran University of Manchester Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
12.40-12.50 Rosa Morra University of Manchester Classical and non-classical secretion pathways in E. coli for periplasmic and extracellular recombinant protein production
12.50-13.15 Jonathan Bones The National Institute for Bioprocessing Research and Training, Ireland Characterisation of biopharmaceuticals using intact protein separations hyphenated to high resolution native mass spectrometry

 

 

 

Gordon Research Conference: Development of biotherapeutics & vaccines

 Hotel Galvez, Texas Gulf coast in Galveston, Texas, USA January 6-10th 2019

https://www.grc.org/biotherapeutics-and-vaccines-development-conference/2019/

Graduate students and post-docs can apply for waiver of registration fee (covers boarding and lodging at the hotel) from the GRC Chairs’ Fund; travel will not be reimbursed. Applications are currently being accepted through the conference web page online, and acceptances will start after the final program is posted in September.

 

Keynote Session: Vaccines and Biotherapeutics Development: Improving Global Healthcare
Brian Kelley (Vir Biotechnology, USA)
Susan Hershenson (Bill and Melinda Gates Foundation, USA)
Gail Wasserman (MedImmune, USA)
Jim Thomas (Just Biotherapeutics, USA)

 

BioProNET-funded collaboration-building workshops

Using big data and computational methods in bioprocessing
June 11th, University of Kent, Canterbury
9.30am (registration), 10am–5.00pm

The continuing advances in computational methods and the greater use of high throughput omics approaches has increased the potential for greater application of these methods in bioprocessing. This workshop will focus on a number of main areas including: 1) antibody design, 2) use of genetic variation when analysing CHO cells for biologics production 3) protein modelling to investigate properties such as aggregation and binding of host cell impurities to biologics.
Confirmed speakers include Charlotte Deane, University of Oxford, Mark Wass, University of Kent and Nicole Borth, Universität für Bodenkultur, Vienna, Austria.
For more details contact Mark Wass
To register: https://www.surveymonkey.co.uk/r/BioProNET_BigData
Travel: If you are coming by train via London, then Canterbury is less than one hour from London St Pancras. More travel details here https://www.kent.ac.uk/locations/canterbury/directions.html

The promise of genome editing: changing bioprocessing, manufacture and much more
18th June, Bradfield Centre, Cambridge Science Park, 11am–4pm
Confirmed speakers include Nicola McCarthy, Horizon Discovery; Mark Fife, Pirbright Institute; Lorenz Mayr, GE Healthcare and Claus Kristensen, University of Copenhagen.
Evolution is so ‘yesterday’ as we enter the revolution offered by genome editing. You may find this opinion provocative but if the cellular systems we have are not good enough for the functions needed, why should we not just build new ones by changing the genetic makeup of the cell, So far, so good… the promise remains but what is the reality of this hope? In this workshop we are bringing together expert opinion leaders from academia and industry to examine the likelihood of the expectations being translated to outcomes. Via short expert presentations and focused group discussions, the participants will examine how the potential of genome editing to change the manufacture of bio-based products may be enhanced and the practical consequences of such interventions from a commercial perspective.

Registration link and more information: http://app1.horizondiscovery.com/biopronet-2018-event-application

Bioprocess Intensification
July 4th, University College London 9.30am–5.30pm
The continued growth of the biopharmaceutical industry is being challenged by a greater number and variety of products than in the past. The industry is also increasingly concerned with the affordability of these products. These key factors means process intensification has become a critical objective. The goal is higher productivity processes to enable small process trains, resulting in cost-effective, lean, and agile manufacturing facilities. The symposium assembles 8 leaders from the biopharmaceutical industry and academia (Line Lundsberg-Nielsen (NNE), Hani El-Sabbahy (3M/UCL), Ajoy Velayudhan (UCL) Peter Levison (Pall), Will Lewis (GSK), Jonathan Souquet (Merck KGaA), John Welsh (Pall) Suzy Farid (UCL)) who will present their latest findings and opinions on the subject. By bringing together scientists and engineers from academia and industry who are actively engaged in bioprocess intensification the event will provide forum for lively debate.

Registration here: https://www.surveymonkey.co.uk/r/BioProNET_BioprocessIntensification
The programme is available here
Directions: https://www.ucl.ac.uk/maps/jz-young-lt